Five-Year Study of Tacrolimus as Secondary Intervention Versus Continuation of Cyclosporine in Renal Transplant Patients at Risk for Chronic Renal Allograft Failure

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Transplantation

• Publication date

  2008-10-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/TP.0b013e318186dd0cPMID 18852662
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Conversion From Cyclosporine to Tacrolimus in Patients at Risk for Chronic Renal Allograft Failure: 60-Month Results of the CRAF Study

  2008cited by this paper
• Banff '05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (‘CAN’)

  2007cited by this paper
• No robust conclusions to be drawn from clinical trials in the absence of an adequate control group

  2007cited by this paper
• Overcoming barriers to long-term graft survival.

  2006cited by this paper
• Slowing the Progression of Chronic Allograft Nephropathy by Conversion from Cyclosporine to Tacrolimus: A Randomized Controlled Trial

  2006cited by this paper
• Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy.

  2006cited by this paper
• No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year.

  2005cited by this paper
• The natural history of chronic allograft nephropathy.

  2005cited by this paper
• Predicting Subsequent Decline in Kidney Allograft Function from Early Surveillance Biopsies

  2005cited by this paper
• Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure

  2005cited by this paper
• Conversion from Cyclosporine to Tacrolimus Improves Quality‐of‐Life Indices, Renal Graft Function and Cardiovascular Risk Profile

  2004cited by this paper
• Long‐Term Renal Allograft Survival: Have we Made Significant Progress or is it Time to Rethink our Analytic and Therapeutic Strategies?

  2004cited by this paper
• Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy

  2004cited by this paper
• A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy.

  2004cited by this paper
• Poor Predictive Value of Serum Creatinine for Renal Allograft Loss

  2003cited by this paper
• Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience.

  2003cited by this paper
• The natural history of chronic allograft nephropathy.

  2003cited by this paper
• Protocol core needle biopsy and histologic Chronic Allograft Damage Index (CADI) as surrogate end point for long-term graft survival in multicenter studies.

  2003cited by this paper
• EFFECT OF HISTOLOGICAL DAMAGE ON LONG-TERM KIDNEY TRANSPLANT OUTCOME

  2001cited by this paper
• A simplified equation to predict glomerular filtration rate from serum creatinine

  2000cited by this paper
• Pathologic classification of chronic allograft nephropathy: pathogenic and prognostic implications.

  1999cited by this paper
• Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study.

  1998cited by this paper
• Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group.

  1998cited by this paper
• Chronic allograft failure: the clinical problem.

  1997cited by this paper
• A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.

  1997cited by this paper
• A Comparison Of Tacrolimus (fk506) And Cyclosporine For Immunosuppression After Cadaveric Renal Transplantation1

  1997cited by this paper
• Cytomegalovirus hyperimmune gammaglobulin downregulates in vitro T-cell responses.

  1996cited by this paper
• Insights into acute and chronic rejection.

  1996cited by this paper
• Pathophysiology of chronic rejection.

  1996cited by this paper
• Intragraft TGF-beta 1 mRNA: a correlate of interstitial fibrosis and chronic allograft nephropathy.

  1996cited by this paper
• Determinants of chronic renal allograft rejection in cyclosporine-treated recipients.

  1996cited by this paper
• Immunosuppressive regimens and their effects on renal allograft outcome.

  1996influential reference
• Intragraft TGF-β1 mRNA: A correlate of interstitial fibrosis and chronic allograft nephropathy

  1996cited by this paper
• Clinical correlation between renal allograft failure and hyperlipidemia.

  1995cited by this paper
• The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival.

  1995cited by this paper
• Design of trials of methods to reduce late renal allograft loss: the price of success.

  1995cited by this paper
• Clinical predictors of chronic renal allograft rejection.

  1995cited by this paper
• Chronic renal allograft failure: clinical overview. The Leuven Collaborative Group for Transplantation.

  1995cited by this paper
• Chronic renal-allograft failure - clinical overview

  1995cited by this paper
• Can histopathological findings in early renal allograft biopsies identify patients at risk for chronic vascular rejection?

  1995cited by this paper
• Regulation of transforming growth factor-beta 1 and its receptor by cyclosporine in human T lymphocytes.

  1995cited by this paper
• Cyclosporine enhances the expression of TGF-beta in the juxtaglomerular cells of the rat kidney.

  1995cited by this paper
• Molecular mechanisms of chronic renal allograft rejection.

  1995cited by this paper
• FK 506: effects on glomerular hemodynamics and on mesangial cells in culture.

  1995cited by this paper
• Lipid-lowering therapy in patients with renal disease.

  1995cited by this paper
• Chronic rejection ‐ Definition and correlates

  1994cited by this paper
• Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12.

  1994cited by this paper
• Risk factors for chronic rejection in renal allograft recipients.

  1993cited by this paper
• Human gene mapping 3. Baltimore Conference (1975). Third International Workshop on Human Gene Mapping. Report of the committee on the genetic constitution of autosomes other than chromosomes 1, 2, and 6.

  1976cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• Early Conversion to Tacrolimus Vs Cyclosporine Continuation in Normally Functioning Kidney Allograft: A Single-Center Study

  2020cites this paper
• Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial

  2017cites this paper
• Tacrolimus Versus Cyclosporine as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation

  2016cites this paper
• Multinational Evaluation of Mycophenolic Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization.

  2016cites this paper
• Cyclosporine Therapy for Kidney Transplant: What is New for an Old-Fashioned Therapy?

  2015cites this paper
• Can a combined screening/treatment programme prevent premature failure of renal transplants due to chronic rejection in patients with HLA antibodies: study protocol for the multicentre randomised controlled OuTSMART trial

  2014cites this paper
• Wirkung von Tacrolimus auf die Synthese von TGF-β1 und die Expression der TGF-β1-Rezeptoren TβRI und TβRII in der Mesangiumzelle

  2014cites this paper
• Conversion to tacrolimus once‐daily from ciclosporin in stable kidney transplant recipients: a multicenter study

  2012cites this paper